MAGEA3 Antibody, FITC conjugated

1. rapid drop (>50%) in blood level within 4 weeks of melanoma treatment associated with long-term response to therapy PMID: 27561960
2. the objective response rate was lower in this study than in other studies carried out in the same setting with the MAGE-A3 immunotherapeutic. Investigation of a gene signatures (GS) to predict clinical benefit to adjuvant MAGE-A3 immunotherapeutic treatment is ongoing in another melanoma study. PMID: 27502712
3. Administering autologous CD4(+) T cells that are genetically engineered to express an MHC class II-restricted antitumor TCR that targets MAGE-A3 can be used safely in the treatment of metastatic neoplasms. PMID: 28809608
4. MAGEA3 may be demethylated in MPNST and plexiform type neurofibroma in NF-1 patients PMID: 27422441
5. MAGEA3 was overexpressed in colorectal cancer tissue compared with healthy colon. MAGEA3 expression positively correlated with colorectal cancer progression. PMID: 27635108
6. Comparing the overall expression of CTAs, a decreased expression of all melanoma-associated antigens (MAGEs) post-treatment and a slightly increased expression of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) was visible. The simultaneous cytoplasmic and nuclear expression of pan-MAGE or MAGE-A3/A4 correlated with reduced treatment-failure-free-survival (TFFS). PMID: 27466502
7. MAGE-A3 expression is regulated epigenetically by promoter methylation, and that its expression contributes to gastric cell proliferation and drug sensitivity. PMID: 26868260
8. Progression free survival and levels of MAGE-A3 expression in non-small cell lung carcinoma patients with the three modes of acquired resistance are negatively correlated. PMID: 26612451
9. the crystal structures of MAGE-A3 and MAGE-A4 PMID: 26910052
10. MAGEA3/6 positivity was associated with significantly better disease-free survival. PMID: 25564441
11. Anticancer effects of adenovirus-mediated calreticulin and melanoma-associated antigen 3 expression on non-small cell lung cancer cells PMID: 25704851
12. our findings indicated that MAGE-A3 is a novel cancer stem cell antigen in bladder cancer PMID: 25031712
13. MAGE-A3 may serve as a potential prognostic marker for clear cell renal cell carcinoma PMID: 25120790
14. Study describes a widespread mechanism to suppress AMPK through its ubiquitination and degradation by the cancer-specific MAGE-A3/6-TRIM28 ubiquitin ligase. MAGE-A3 and MAGE-A6 are highly similar proteins normally expressed only in the male germline but frequently re-activated in human cancers. PMID: 25679763
15. MAGE proteins bind to KAP1, a gene repressor and ubiquitin E3 ligase which also binds KRAB domain containing zinc finger transcription factors (KZNFs), and MAGE expression may affect KZNF mediated gene regulation. PMID: 25107531
16. Study demonstrated that the expression of MAGE-A3/4 antigen might be a valuable prognostic factor regarding survival in patients with NSCLC. PMID: 24675493
17. Data indicate that MAGE3, Survivin and B-cell maturation antigen (BCMA) mRNA-pulsed dendritic cells (DCs) are capable of stimulating tumor-associated antigens (TAA)-specific T-cell responses in multiple myeloma (MM) patients. PMID: 23728352
18. Cells bearing either intermediate proteasome present peptides MAGE-A(3114-122) and MAGE-C2(42-50) as efficiently as cells equipped with the immunoproteasome. PMID: 22925930
19. High MAGE-3 gene expression is associated with metastases in hepatitis C virus patients complicated by hepatocellular carcinoma. PMID: 21452042
20. the expression of MAGE, as confirmed in the RT-PCR analysis, could be used as an alternative method for the early diagnosis of salivary gland tumours. PMID: 22498264
21. Report MAGEA1-A6 expression and MAGE A3 methylation in sputum suggests presence of lung cancer cells or precancerous cells. PMID: 22134685
22. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. PMID: 22323448
23. Data indicate the association of MAGE-A3 expression and poor prognosis in diffuse large B-cell lymphoma (DLBCL) patients. PMID: 22183072
24. MAGE-A3 gene may have a clinical relevance and important role as a risk factor in the development of acute myeloid leukemia PMID: 21804405
25. Expression of MAGE I proteins, MAGE-A3 or MAGE-C2, relieved repression of a reporter gene by ZNF382 and MAGE I expression relieved KAP1 mediated ID1 repression. PMID: 21876767
26. we found that the SSX4 and MAGE-A3 genes are frequently expressed in brain tumor cell lines PMID: 21347689
27. MAGE-A3 was detected in a significantly higher percentage of relapsed patients compared with newly diagnosed, establishing a novel correlation with progression of disease. PMID: 21565982
28. MAGE-A3, a cancer-testis antigen, plays an important role in the survival of multiple myeloma cells. PMID: 20015885
29. Primary tumors with and without lymph node metastases showed no significant differences in MAGE-A 3/4 (P=0.672) and NY-ESO-1 (P=0.444) expression PMID: 21556122
30. RT-PCR assays of MAGE-A3 and MAGE-A4 in blood of breast cancer (BC) patients may have prognostic and predictive implications, and they are promising specific tumor markers of BC PMID: 21264495
31. MAGE3 expression mediated by demethylation of MAGE3 promoter induce progression of non-small cell lung cancer. PMID: 21273595
32. Molecular upstaging of MAGE-A3 using rt-pcr was correlated with prognosis in melanoma patients PMID: 21135695
33. Report immunohistochemical expression of MAGE-A3 in renal oncocytoma and chromophobe renal cell carcinoma. PMID: 20591578
34. results showed that MAGE-A3 gene expression was frequent in NHL patients and decreased after effective chemotherapy, suggesting that MAGE-A3 can be used as a tumor marker for circulating lymphoma cells in patients with NHL. PMID: 20036422
35. Tumor-specific antigen MAGE may play a role in the occurrence and development of ovarian cancer and can be used as one of the important indicators for early diagnosis, efficacy evaluation and prognostic determination of ovarian cancer. PMID: 20423514
36. MAGE-A3/6 and NY-ESO-1 were expressed in 50.0% (66/132) and 18.2% (24/132) of non-small-cell lung carcinomas, respectively. PMID: 19795170
37. Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3 PMID: 12393675
38. This melanoma-associated marker was detected in melanoma cell lines. PMID: 12710945
39. first evidence that the naturally processed MAGE-3(271-279) can be isolated and identified from the tumor tissue of hepatocellular carcinoma patient PMID: 15885805
40. The newly identified MAGE-3(113)-peptide epitope is naturally processed and presented as the CTL epitope on MAGE-3-expressing GI cancer cells, indicating that anti-MAGE-3 immune targeting with the MAGE-3(113) peptide is a promising approach for treatment. PMID: 16446550
41. MAGE-A3 gene mRNA is expressed at the mRNA level in a proportion of human leukemias. PMID: 16806467
42. The promoter hypomethylation of MAGE-A1 and MAGE-A3 genes up-regulates their expression in colorectal carcinomas as well as in gastric cancers and might play a significant role in the development and progression of human colorectal carcinomas. PMID: 17007017
43. Gene expression profiling identified the cancer/testis antigen MAGE-A3/6 as a novel target of FGFR2-IIIb signaling. PMID: 17699848
44. Measurement of Melan-A, gp100, MAGE-3, MIA and tyrosinase represents a prognostic factor and a method for early detection of metastasis and treatment response of melanoma patients. PMID: 18181974
45. MAGEC1/CT7, MAGEA3/6 and LAGE-1 are good candidates for immunotherapy, since together they cover 85% of our MM cases. PMID: 18237105
46. the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells are influenced by endosomal proteases PMID: 18316621
47. MAGE-A3 as a target of FGFR2-IIIb and estrogen action and provide evidence for a common histone-modifying network in the control of the balance between opposing signals. PMID: 18381936
48. MAGE-A3 may have a role in melanoma and could be used in a therapeutic vaccine PMID: 18483279
49. MAGE A3 is a functional integrator of diverse signals, including FGFR2 and FN, to modulate cancer progression. PMID: 18829569
50. Its expression is significantly associated with prognostic factors in poor outcome of the non-small cell lung cancer PMID: 18982744

Show More

Hide All

HGNC: 6801

OMIM: 300174

KEGG: hsa:4102

STRING: 9606.ENSP00000359301

UniGene: Hs.417816